2024
Luteal phase sertraline treatment of premenstrual dysphoric disorder (PMDD): Effects on markers of hypothalamic pituitary adrenal (HPA) axis activation and inflammation
Barone J, Ho A, Osborne L, Eisenlohr-Moul T, Morrow A, Payne J, Epperson C, Hantsoo L. Luteal phase sertraline treatment of premenstrual dysphoric disorder (PMDD): Effects on markers of hypothalamic pituitary adrenal (HPA) axis activation and inflammation. Psychoneuroendocrinology 2024, 169: 107145. PMID: 39096755, PMCID: PMC11381144, DOI: 10.1016/j.psyneuen.2024.107145.Peer-Reviewed Original ResearchPremenstrual dysphoric disorderSertraline treatmentMultilevel linear modelsDysphoric disorderHypothalamic pituitary gonadalHypothalamic pituitary adrenal (HPA) axisEffects of sertraline treatmentHypothalamic pituitary adrenal (HPA) axis activityPMDD patientsPMDD statusOpen-label sertralineMildly stressful tasksPremenstrual dysphoric disorder groupDaily symptom ratingsSevere affective symptomsEffect of groupPremenstrual symptom severityMenstrual cycle phaseAssociated with higher levelsALLO levelsInflammatory markersMenstrual cycleAffective symptomsAffective disordersClinical Interview
2023
GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder
Miller K, Standeven L, Morrow A, Payne J, Epperson C, Hantsoo L. GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder. Psychoneuroendocrinology 2023, 160: 106684. PMID: 38091917, PMCID: PMC10846389, DOI: 10.1016/j.psyneuen.2023.106684.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderSelective serotonin reuptake inhibitorsGABAergic neuroactive steroidsNeuroactive steroid levelsNeuroactive steroidsSertraline treatmentGABA-A receptorsLuteal phasePregnanolone levelsPMDD groupSerum levelsProgesterone ratioDysphoric disorderSteroid levelsSerotonin reuptake inhibitorsPlacebo-controlled designSubsequent luteal phaseEffect of GABAMenstrual cycle phaseNegative mood symptomsGamma-aminobutyric acidPMDD treatmentSSRI treatmentSSRI sertralineReuptake inhibitorsDoes Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?
Yonkers K, Altemus M, Gilstad-Hayden K, Kornstein S, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder? Journal Of Clinical Psychopharmacology 2023, 43: 320-325. PMID: 37212651, PMCID: PMC10313784, DOI: 10.1097/jcp.0000000000001700.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderFunctional impairmentSymptom onsetPMDD symptomsDysphoric disorderAnger/irritabilityDaily treatmentActive treatmentFunctional outcomeClinical trialsFunctional improvementSecondary analysisCausal mediation analysisSertralineSeverity of problemsImpairmentNonsignificant direct effectDaily ratingsPlaceboTreatmentFace validitySymptomsIrritabilityDisordersSignificant indirect effect
2015
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2015, 72: 1037-1044. PMID: 26351969, PMCID: PMC4811029, DOI: 10.1001/jamapsychiatry.2015.1472.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderSymptom-onset dosingSerotonin reuptake inhibitorsDays of mensesSSRI withdrawalSymptom onsetSymptomatic daysMenstrual cycleClinical trialsDysphoric disorderOutcome measuresScale scoreSRI treatmentTreatment of PMDDClinical Global Impression ScaleAbrupt treatment cessationDepressive Symptomatology-ClinicianTotal DRSP scoresSecondary outcome measuresPrimary outcome measureGlobal Impression ScaleIDS-C scoresUniversity Medical CenterSertraline hydrochlorideBeginning of menses
2014
Selective Serotonin Reuptake Inhibitors and Endothelial Function in Women
Hantsoo L, Czarkowski KA, Child J, Howes C, Epperson CN. Selective Serotonin Reuptake Inhibitors and Endothelial Function in Women. Journal Of Women's Health 2014, 23: 613-618. PMID: 24886268, PMCID: PMC4089019, DOI: 10.1089/jwh.2013.4623.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBlood Flow VelocityBrachial ArteryDepression, PostpartumDepressive Disorder, MajorEndothelium, VascularFemaleFollow-Up StudiesHumansMiddle AgedNitric OxidePlatelet AggregationPremenstrual SyndromeSelective Serotonin Reuptake InhibitorsTreatment OutcomeUltrasonography, DopplerVasodilationYoung AdultConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsSSRI treatmentPremenstrual dysphoric disorderCardiovascular diseasePlatelet aggregationNO productionReuptake inhibitorsPostpartum depressionEffects of SSRIsBurden of diseasePlatelet NO productionDepression/anxietyNitric oxide functionSSRI therapyEndothelial functionVascular mechanismsVascular dilatationMajor depressionDysphoric disorderNormal rangeBeck DepressionYounger groupDiseaseWomen
2013
Premenstrual Syndrome/Premenstrual Dysphoric Disorder and Mood Disorders
Dobbs M, Braverman P. Premenstrual Syndrome/Premenstrual Dysphoric Disorder and Mood Disorders. 2013, 281-284. DOI: 10.1002/9781118538555.ch42.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPremenstrual dysphoric disorderDysphoric disorderPremenstrual syndromeSevere PMS/PMDDPremenstrual syndrome/premenstrual dysphoric disorderSelective serotonin reuptake inhibitorsPMS/premenstrual dysphoric disorderNonpharmacologic treatment modalitiesSpecific presenting symptomsOnset of mensesOral contraceptive pillsSerotonin reuptake inhibitorsMenstrual-related symptomsPostmenarchal womenPresenting symptomPharmacologic treatmentBreast tendernessReuptake inhibitorsContraceptive pillsTreatment modalitiesMild casesLuteal phaseMood disordersPhysical symptomsAffective symptoms
2012
Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5
Epperson CN, Steiner M, Hartlage SA, Eriksson E, Schmidt PJ, Jones I, Yonkers KA. Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5. American Journal Of Psychiatry 2012, 169: 465-475. PMID: 22764360, PMCID: PMC3462360, DOI: 10.1176/appi.ajp.2012.11081302.Peer-Reviewed Original ResearchCriteria for Premenstrual Dysphoric Disorder: Secondary Analyses of Relevant Data Sets
Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for Premenstrual Dysphoric Disorder: Secondary Analyses of Relevant Data Sets. JAMA Psychiatry 2012, 69: 300-305. PMID: 22393222, PMCID: PMC3370334, DOI: 10.1001/archgenpsychiatry.2011.1368.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderDays of mensesDSM-IVPMDD symptomsDysphoric disorderMain outcome measuresOptimal cutoff pointNumber of symptomsSymptomatic periodMenstrual cycleProspective surveyOutcome measuresPerimenstrual symptomsPsychiatric disordersMore symptomsAffective symptomsCutoff pointPhysical symptomsPremenstrual phaseSecondary analysisSymptomsProblematic symptomsClinical settingDepressed moodCohort
2010
Menstrual cycle-related exacerbation of disease
Pinkerton JV, Guico-Pabia CJ, Taylor HS. Menstrual cycle-related exacerbation of disease. American Journal Of Obstetrics And Gynecology 2010, 202: 221-231. PMID: 20207238, PMCID: PMC3107848, DOI: 10.1016/j.ajog.2009.07.061.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderMenstrual cycleDysphoric disorderPerimenopausal depressionCommon mental health problemsPrimary care providersCommon psychiatric disordersMental health disordersMental health problemsAntidepressant agentsTreatment optionsDepressive disorderLuteal phaseRoutine screeningCare providersEffective treatmentPsychiatric disordersHealth disordersHealth problemsAccurate diagnosisNeuroendocrine systemPrecise causeDisordersExacerbationDepression
2009
Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder
Breech L, Braverman P. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. International Journal Of Women's Health 2009, 1: 85-95. PMID: 21072278, PMCID: PMC2971718, DOI: 10.2147/ijwh.s4338.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsOral contraceptive pillsPremenstrual dysphoric disorderPlacebo-controlled trialContraceptive pillsDysphoric disorderTherapeutic modalitiesLarge randomized placebo-controlled trialsLow-dose oral contraceptive pillDouble-blind placebo-controlled trialBlinded placebo-controlled trialNew oral contraceptive pillRandomized placebo-controlled trialTreatment of PMDDFluid retention symptomsOpen-label studyReproductive-age womenSignificant placebo effectMultiple therapeutic modalitiesBetter patient compliancePromising therapeutic modalityNovel progestinRetention symptomsBlood pressureSerum potassiumThrombotic events
2008
Pharmaceutical Industry Marketing: Understanding Its Impact on Women’s Health
Sufrin CB, Ross JS. Pharmaceutical Industry Marketing: Understanding Its Impact on Women’s Health. Obstetrical & Gynecological Survey 2008, 63: 585-596. PMID: 18713478, DOI: 10.1097/ogx.0b013e31817f1585.Commentaries, Editorials and LettersConceptsWomen's healthOral contraceptive pillsEvidence-based careHealth carePremenstrual dysphoric disorderPharmaceutical marketingContraceptive pillsDysphoric disorderModern health carePhysician behaviorCytology techniqueConsumer advertisingCarePatientsHealthPhysiciansSubstantial evidenceSignificant involvementPractice of medicineDrugsDiscussion of guidelinesProphylaxisProfessional organizationsPillsWomenPremenstrual syndrome
Yonkers KA, O'Brien P, Eriksson E. Premenstrual syndrome. The Lancet 2008, 371: 1200-1210. PMID: 18395582, PMCID: PMC3118460, DOI: 10.1016/s0140-6736(08)60527-9.Peer-Reviewed Original ResearchConceptsSevere premenstrual syndromePremenstrual dysphoric disorderPremenstrual syndromeSerotonin reuptake inhibitorsGonadal hormone levelsGonadotropin-releasing hormoneOral contraceptivesReuptake inhibitorsBreast tendernessSerotonergic synapsesReproductive ageHormone levelsDysphoric disorderLuteal phaseOvary axisMost womenOvarian cyclicityBehavioral symptomsDepressed moodSymptomsMood swingsSomatic complaintsPhysical discomfortWomenDaily activities
2007
Luteal-Phase Accentuation of Acoustic Startle Response in Women with Premenstrual Dysphoric Disorder
Epperson CN, Pittman B, Czarkowski KA, Stiklus S, Krystal JH, Grillon C. Luteal-Phase Accentuation of Acoustic Startle Response in Women with Premenstrual Dysphoric Disorder. Neuropsychopharmacology 2007, 32: 2190-2198. PMID: 17314917, PMCID: PMC2713599, DOI: 10.1038/sj.npp.1301351.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderMenstrual cycle phaseMenstrual cycleHealthy womenFollicular phaseDysphoric disorderLuteal phasePhysiologic responsesMenstrual cycle-related fluctuationsStartle magnitudeCentral nervous system responseHealthy menstruating womenAcoustic startle responseAcoustic startle paradigmNervous system responsesPowerful modulatory effectsStartle response magnitudeVisual affective stimuliNeuroactive steroidsMenstruating womenASR magnitudeModulatory effectsCycle phaseNeuroendocrine milieuAcoustic startle response magnitudes
2005
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. Obstetrics And Gynecology 2005, 106: 492-501. PMID: 16135578, DOI: 10.1097/01.aog.0000175834.77215.2e.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderPlacebo groupSymptom scoresDysphoric disorderNew low dose oral contraceptiveLow-dose oral contraceptivesBehavioral symptom scoresActive treatment groupDaily symptom scoresPhysical symptom scoresEthinyl estradiol groupInactive pillsOral contraceptivesEstradiol groupClinical trialsEthinyl estradiolTreatment cyclesTotal Daily RecordI. EfficacyDrospirenoneSymptomsPill formulationDisordersOCP formulationsPlaceboPretreatment pattern of symptom expression in premenstrual dysphoric disorder
Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal Of Affective Disorders 2005, 85: 275-282. PMID: 15780697, DOI: 10.1016/j.jad.2004.10.004.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderPMDD symptomsMenstrual cycleDysphoric disorderPatient variabilityIntermittent dosing strategyOnset of menstruationDSM-IV criteriaPatients' durationAnxiety/tensionSertraline treatmentDRSP scoresPatient daysDosing strategiesSevere symptomsDay 2SymptomsTreatment studiesPretreatment patternAnger/irritabilityMood swingsMore daysWomenSymptom expressionTreatment implications
2003
Premenstrual disorders: bridging research and clinical reality
Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Archives Of Women's Mental Health 2003, 6: 287-292. PMID: 14628181, DOI: 10.1007/s00737-003-0026-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultConnecticutDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersFemaleHumansPatient Acceptance of Health CarePatient SelectionPremenstrual SyndromePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSelf-AssessmentSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeConceptsPremenstrual dysphoric disorderPremenstrual symptomsTreatment resultsBrief Patient Health QuestionnaireConcurrent psychiatric conditionsOb-gyn settingsStatistical Manual IV criteriaSerotonin reuptake inhibitorsUsual care settingsPatient Health QuestionnaireMinor depressive disorderActual clinical practiceTypes of symptomsEligible womenPatient characteristicsReuptake inhibitorsOpen trialSymptomatic subgroupCurrent comorbidityIV criteriaClinical trialsDepressive disorderHealth QuestionnaireTypical patientDysphoric disorder
2002
Cortical γ-Aminobutyric Acid Levels Across the Menstrual Cycle in Healthy Women and Those With Premenstrual Dysphoric Disorder: A Proton Magnetic Resonance Spectroscopy Study
Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, Weiss E, Rothman DL, Krystal JH. Cortical γ-Aminobutyric Acid Levels Across the Menstrual Cycle in Healthy Women and Those With Premenstrual Dysphoric Disorder: A Proton Magnetic Resonance Spectroscopy Study. JAMA Psychiatry 2002, 59: 851-858. PMID: 12215085, DOI: 10.1001/archpsyc.59.9.851.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderCortical GABA levelsGABA neuronal functionBrain GABA concentrationsHealthy womenMenstrual cycleGABA levelsNeuronal functionNeuroactive steroidsFollicular phaseDysphoric disorderGABA concentrationOccipital cortex GABA levelsProton magnetic resonance spectroscopy studyUniversity-based medical centerHealthy menstruating womenΓ-aminobutyric acid (GABA) levelsMagnetic resonance spectroscopy studyLate luteal phaseMenstrual cycle phaseHealth Research programmeMid lutealNeurosteroid levelsGABAergic systemMenstruating women
2001
Venlafaxine in the treatment of premenstrual dysphoric disorder.
Freeman E, Rickels K, Yonkers K, Kunz N, McPherson M, Upton G. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstetrics And Gynecology 2001, 98: 737-44. PMID: 11704162, DOI: 10.1016/s0029-7844(01)01530-7.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderDaily symptom reportsTreatment of premenstrual dysphoric disorderDysphoric disorderHamilton Rating Scale for DepressionPremenstrual dysphoric disorder treatmentDSR scoresEfficacy of long-term maintenance treatmentSafety of venlafaxineFlexible-dose trialNew-generation antidepressantsLong-term maintenance treatmentDouble-blind treatmentTreatment cyclesPremenstrual symptom scoresVenlafaxine doseVenlafaxine treatmentSymptom reductionSymptom remissionInhibit serotoninNorepinephrine reuptakePMDD symptomsVenlafaxineSymptom reportingCyclic disorder
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply